No Picture
News

Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris

-Top-line results expected June 2020

SAN DIEGO, Feb. 11, 2020 /PRNewswire/ — Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial evaluating th… […]

No Picture
News

Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call

SAN DIEGO, Feb. 10, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and … […]

No Picture
News

DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020

SAN DIEGO, Feb. 5, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Mr. Saiid Zarrabian, Ch… […]

No Picture
News

DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

February Issue of “Glioma” Highlights Positive Progression-Free Survival Data

SAN DIEGO, Jan. 29, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of… […]